Abstracts tagged "rheumatoid arthritis"

Abstract Number: 3136 • 2015 ACR/ARHP Annual Meeting
Impact of Prokinetic Agents on Systemic Sclerosis-Associated Gastrointestinal Disease: A Systematic Review
Annaliese Tisseverasinghe¹, Ahmad Kadhim², Ambica Parmar², Louis Liu² and Sindhu R. Johnson¹, ¹Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, Mount Sinai Hospital, Institue of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Division of Gastroenterology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: More than 90% of patients with Systemic Sclerosis (SSc) have gastroinstestinal (GI) involvement, commonly dysmotility causing complications such as gastroesophageal reflux and constipation. Treatment…
Abstract Number: 1648 • 2015 ACR/ARHP Annual Meeting
The Balance of Foxp3/Ror-Gammat Expression Is Altered By Tocilizumab and By Abatacept in Patients with Rheumatoid Arthritis
Yoshifumi Tada¹, Syuichi Koarada², Nobuyuki Ono², Akihito Maruyama², Satoko Tashiro², Yukiko Tokuda², Yukihide Ono², Yoshinobu Nakao² and Akihide Ohta³, ¹Department of Internal Medicine, Division of Rheumatology, Saga University, Saga, Japan, ²Rheumatology, Saga University, Saga, Japan, ³Department of Adult and Gerontological Nursing, Saga University School of Medicine, Saga, Japan
Background/Purpose: It has been shown that the balance between Th17 cells and regulatory T (Treg) cells plays an important role for the development of autoimmune…
Abstract Number: 3191 • 2015 ACR/ARHP Annual Meeting
Siglec9 Suppresses Arthritis in Collagen-Induced Mice Model and Inhibits M1 Activation of RAW264.7 Macrophages
Takuya Matsumoto¹, Nobunori Takahashi¹, Toshihisa Kojima¹ and Naoki Ishiguro², ¹Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ²Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: Siglecs (Sialic acid-binding immunoglobulin-type lectins) are type1 transmembrane proteins and expressed on cell surface of various immunocytes. Siglec9 is a member of CD33 related…
Abstract Number: 1656 • 2015 ACR/ARHP Annual Meeting
Repeated CD4+ T-Cell Depletion in Patients with Rheumatoid Arthritis over Multiple Cycles of Rituximab Treatment
Matthieu Lavielle¹, Denis Mulleman¹, Hsueh Cheng Sung², Clément Bahuaud², Philippe Goupille¹, Hervé Watier³ and Gilles Thibault³, ¹Service de Rhumatologie, CHRU de Tours, Université François-Rabelais de Tours, CNRS 7292, Tours, France, ²Université François-Rabelais de Tours, CNRS 7292, Tours, France, ³Laboratoire d'Immunologie, CHRU de Tours, Université François-Rabelais de Tours, CNRS 7292, Tours, France
Background/Purpose: CD4+ T-cell depletion after a first cycle of rituximab (RTX) in patients with rheumatoid arthritis (RA) was previously reported by our group (Mélet J…
Abstract Number: 3198 • 2015 ACR/ARHP Annual Meeting
Treatment of Rheumatoid Arthritis with an Anti-Tumor Necrosis Factor Agent or Tocilizumab As First Biologic Therapy in a Global Comparative Observational Study
Ernest H. Choy¹, Corrado Bernasconi², Maher Aassi², Jose F. Molina³ and Oscar M. Epis⁴, ¹Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Centro Integral de Reumatologia Reumalab, Medellin, Colombia, ⁴Rheumatology Unit, A.O. Ospedale Niguarda Ca' Granda, Milan, Italy
Background/Purpose: ACT-iON was a global, multicenter, observational, 52-wk, clinical practice study of the effectiveness of tocilizumab (TCZ) vs anti–tumor necrosis factor (aTNF) agents prescribed as…
Abstract Number: 1667 • 2015 ACR/ARHP Annual Meeting
Clinical Parameters and B Cell Subsets As Biomarkers of Response to Tocilizumab in Rheumatoid Arthritis
Anna Laura Fedele, Barbara Tolusso, Elisa Gremese, Silvia Canestri, Clara Di Mario, Marcin Nowik and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: Tocilizumab (TCZ) is an effective treatment for Rheumatoid Arthritis (RA) and it is a modifier of B cell subsets in vivo, inducing changes in…
Abstract Number: 175 • 2015 ACR/ARHP Annual Meeting
Correlating Semiquantitative Ultrasound Scores with Measured Synovial Thickness
Ralf G. Thiele¹, Darren Tabechian¹, Laura C Coates² and Jennifer H. Anolik¹, ¹University of Rochester Medical Center, Rochester, NY, ²Medicine, University of Rochester, Rochester, NY
Background/Purpose: In studies of rheumatoid arthritis using ultrasonography (US), findings of synovial thickening are often reported in semiquantitative scores. For synovial biopsies of small joints,…
Abstract Number: 1682 • 2015 ACR/ARHP Annual Meeting
Suppression of Chronic Arthritis By a Novel Nuclear Factor of Activated T-Cell 5 (NFAT5) Inhibitor
Wan-Uk Kim¹, Eun-Jin Han², Chong-Hyeon Yoon³, Ki-Jo Kim⁴, Seung-Ah Yoo⁵, Bong Ki Hong⁵ and Saseong Lee⁵, ¹Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, ²Institute of Bone & Joint Disease, The Catholic University of Korea, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁴St. Mary's Hospital, Seoul, South Korea, ⁵Institute of Bone and Joint Diseases, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: We reported that nuclear factor of activated T-cells 5 (NFAT5), originally identified as an osmo-protective transcription factor, has a critical role in the pathogenesis…
Abstract Number: 450 • 2015 ACR/ARHP Annual Meeting
Use of Tofacitinib in a Real World Setting: Clinical Features in a Cohort of Patients Using the Database Jointman Compared to a Published Clinical Trial
Sergio Schwartzman¹, Keith Knapp², Gary Craig³, Karen Ferguson⁴ and Howard Kenney⁵, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Arthritis Northwest, Spokane, WA, ³Discus Analytics, Inc., Spokane, WA, ⁴Arthritis Northwest PLLC., Spokane, WA, ⁵Rheumatology, Arthritis Northwest, Spokane, WA
Background/Purpose: It is well accepted that patients studied in pharmaceutically sponsored clinical trials do not always represent the types of patients seen in clinical practice. …
Abstract Number: 2012 • 2015 ACR/ARHP Annual Meeting
TNF Confers Pathogenic Memory in Synovial Fibroblasts Via Chromatin Remodeling, NF-Kb-Dependent Transcription and MAPK-Mediated mRNA Stabilization
Konstantinos Loupasakis¹, Christopher Sohn², Lionel B. Ivashkiv³ and George D. Kalliolias², ¹Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY
Background/Purpose: We investigated mechanisms driving pathogenic behavior of synovial fibroblasts (FLS) in rheumatoid arthritis (RA). Methods: FLS from RA patients (1987 classification criteria) were extracted.…
Abstract Number: 544 • 2015 ACR/ARHP Annual Meeting
IL-6 May Have an Important Role in the Resistance to Anti-TNF Therapies of Human T-Lymphotropic Virus Type 1 (HTLV-1) Positive Rheumatoid Arthritis (RA) Patients; HTLV-1 Infected Cells Activate the Inflammatory Responses of RA Synovial Fibroblasts
Kunihiko Umekita¹, Shunichi Miyauchi¹, Kazuyoshi Kubo¹, Kazumi Umeki¹, Hajime Nomura¹, Mao Komura¹, Koushou Iwao¹, Ichiro Takajo¹, Yasuhiro Nagatomo¹, Toshihiko Hidaka² and Akihiko Okayama¹, ¹Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Miyazaki, Japan, ²Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan
Background/Purpose: We reported that human T-lymphotropic virus type 1 (HTLV-1) positive patients with rheumatoid arthritis (RA) had higher inflammation and greater resistance to anti-TNF treatment…
Abstract Number: 2102 • 2015 ACR/ARHP Annual Meeting
Higher Persistence and Adherence with Combination Therapy with Tumor Necrosis Factor Inhibitor+Methotrexate Combination Versus Triple Therapy in US Veterans with Rheumatoid Arthritis
Brian Sauer¹, Chia-Chen Teng², Jianwei Leng³, Ted R. Mikuls⁴, Jeffrey R. Curtis⁵, Bradley S. Stolshek⁶, Derek Tang⁶ and Grant W. Cannon⁷, ¹IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ²HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ³Internal Medicine Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Amgen, Inc., Thousand Oaks, CA, ⁷Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT

Background/Purpose: Randomized controlled trials in RA have reported efficacy with both triple therapy (methotrexate [MTX] + hydroxychloroquine [HCQ] + sulfasalazine [SSZ]) and tumor necrosis factor…
Abstract Number: 582 • 2015 ACR/ARHP Annual Meeting
Biological Drugs Dose Tapering in Inflammatory Rheumatic Diseases: 2 Year Results at Basurto University Hospital
Juan María Blanco-Madrigal¹, Maria Luz Garcia Vivar¹, Catalina Gomez Arango¹, Olaia Fernández Berrizbeitia¹, Clara Perez Velasquez¹, Ignacio Torre Salaberri², Jose Francisco Garcia Llorente³, Eva Galindez-Agirregoikoa⁴, Esther Ruiz Lucea¹ and Iñigo Gorostiza⁵, ¹Rheumatology, Basurto University Hospital, Bilbao, Spain, ²Rheumaytology, Basurto University Hospital, Bilbao, Spain, ³Rheumatology, Basurto University Hospital., Bilbao, Spain, ⁴Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain, ⁵Research Department, BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain
Background/Purpose: Last years, biological dose tapering in patients with inflammatory diseases has become a routine clinical practice. Since 2011 we are applying a dose reduction…
Abstract Number: 2546 • 2015 ACR/ARHP Annual Meeting
Targeting Synovial Fibroblasts By the Intra-Articular Delivery of microRNA-140-3p and -5p Ameliorates Experimental Autoimmune Arthritis
Chrong-Reen Wang¹, Jia-Shiou Peng², Shih-Yao Chen³, Chao-Liang Wu⁴ and Ai-Li Shiau⁵, ¹Rheum/Immun Sec/Int Med Dept, Medical Coll/Nat'l Cheng Kung, Tainan, Taiwan, ²Institute of Basic Medical Sciences, Medical Coll/Nat'l Cheng Kung, Tainan, Taiwan, ³Internal Medicine, Medical Coll/Nat'l Cheng Kung, Tainan, Taiwan, ⁴Biochemistry and Molecular Biology, Medical Coll/Nat'l Cheng Kung, Tainan, Taiwan, ⁵Microbiology and Immunology, College of Medicine, National Cheng Kung University, Medical Coll/Nat'l Cheng Kung, Tainan, Taiwan
Background/Purpose: Synovial fibroblasts (SF) with aberrant expression of microRNAs (miRNA) are critical pathogenic regulators of rheumatoid joint, and studies examining the effect of overexpressing or…
Abstract Number: 1038 • 2015 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Alpha and Peptidylarginine Deiminase 4 in Lung and Joint Inflammation
Mandar Bawadekar¹, Annette Gendron-Fitzpatrick², Thomas F. Warner³, Lennart K.A. Lundblad⁴, Paul Thompson⁵ and Miriam A. Shelef^1,6, ¹Medicine, University of Wisconsin, Madison, WI, ²Comparative Pathology Laboratory of the Research Animal Resources Center and Pathobiological Sciences, University of Wisconsin, Madison, WI, ³Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI, ⁴Medicine, The University of Vermont, Burlington, VT, ⁵University of Massachusetts, Worcester, MA, ⁶Medicine, William S. Middleton Memorial Veterans Hospital, Madison, WI
Background/Purpose: The relationship between lung and joint inflammation in rheumatoid arthritis is poorly understood. About 10% of people with rheumatoid arthritis develop interstitial lung disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].